Real-World check on new lung cancer drug

NCT ID NCT04575025

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study monitored patients taking Tabrecta, a drug for a specific type of advanced lung cancer, after it was approved for use. It followed 109 patients for up to one year to collect real-world information on side effects and how well the drug worked. The goal was to understand the drug's safety and its impact on survival and disease progression in everyday medical practice.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Kōnan, Aichi-ken, 4838704, Japan
Novartis Investigative Site

Nagoya, Aichi-ken, 457-0818, Japan
Novartis Investigative Site

Nagoya, Aichi-ken, 462-0057, Japan
Novartis Investigative Site

Nagoya, Aichi-ken, 464 8681, Japan
Novartis Investigative Site

Okazaki, Aichi-ken, 444-8553, Japan
Novartis Investigative Site

Toyoake, Aichi-ken, 470 1192, Japan
Novartis Investigative Site

Toyota, Aichi-ken, 470-0343, Japan
Novartis Investigative Site

Daisen, Akita, 014-0027, Japan
Novartis Investigative Site

Hachinohe, Aomori, 031-0011, Japan
Novartis Investigative Site

Sakura, Chiba, 285-8741, Japan
Novartis Investigative Site

Fukui-shi, Fukui, 918-8501, Japan
Novartis Investigative Site

Yoshida-gun, Fukui, 910-1193, Japan
Novartis Investigative Site

Fukuoka, Fukuoka, 811-1395, Japan
Novartis Investigative Site

Fukuoka, Fukuoka, 812-8582, Japan
Novartis Investigative Site

Fukuoka, Fukuoka, 814 0180, Japan
Novartis Investigative Site

Iizuka, Fukuoka, 820-0076, Japan
Novartis Investigative Site

Kitakyushu, Fukuoka, 802-0077, Japan
Novartis Investigative Site

Kitakyushu, Fukuoka, 8058508, Japan
Novartis Investigative Site

Kitakyushu, Fukuoka, 806-8501, Japan
Novartis Investigative Site

Fukushima, Fukushima, 960 1295, Japan
Novartis Investigative Site

Ōgaki, Gifu, 503-8502, Japan
Novartis Investigative Site

Higashihiroshima, Hiroshima, 739-0041, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 003-0804, Japan
Novartis Investigative Site

Akashi, Hyōgo, 673-8558, Japan
Novartis Investigative Site

Himeji, Hyōgo, 670-8520, Japan
Novartis Investigative Site

Nishinomiya, Hyōgo, 663 8501, Japan
Novartis Investigative Site

Tsuchiura, Ibaraki, 300-0028, Japan
Novartis Investigative Site

Tsukuba, Ibaraki, 305-8558, Japan
Novartis Investigative Site

Kan’onjichō, Kagawa-ken, 769-1695, Japan
Novartis Investigative Site

Sakaidechō, Kagawa-ken, 762-8550, Japan
Novartis Investigative Site

Takamatsu, Kagawa-ken, 760-0017, Japan
Novartis Investigative Site

Fujisawa, Kanagawa, 251-8550, Japan
Novartis Investigative Site

Kawasaki, Kanagawa, 216-8511, Japan
Novartis Investigative Site

Sagamihara, Kanagawa, 252-0375, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 220-8521, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 221-0855, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 232 0024, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 234-0054, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 236 0037, Japan
Novartis Investigative Site

Tsu, Mie-ken, 514-8507, Japan
Novartis Investigative Site

Yokkaichi, Mie-ken, 510-8567, Japan
Novartis Investigative Site

Miyakonojō, Miyazaki, 885-0014, Japan
Novartis Investigative Site

Matsumoto, Nagano, 390-8621, Japan
Novartis Investigative Site

Nagasaki, Nagasaki, 852-8501, Japan
Novartis Investigative Site

Kurashiki, Okayama-ken, 701-0192, Japan
Novartis Investigative Site

Okayama, Okayama-ken, 700-8558, Japan
Novartis Investigative Site

Kishiwada, Osaka, 596-8501, Japan
Novartis Investigative Site

Osaka, Osaka, 534-0021, Japan
Novartis Investigative Site

Osaka, Osaka, 540-0006, Japan
Novartis Investigative Site

Osaka, Osaka, 541-8567, Japan
Novartis Investigative Site

Osaka, Osaka, 543-8555, Japan
Novartis Investigative Site

Saga, Saga-ken, 849-8501, Japan
Novartis Investigative Site

Kawaguchi, Saitama, 332-8558, Japan
Novartis Investigative Site

Kumagaya, Saitama, 360-0197, Japan
Novartis Investigative Site

Saitama, Saitama, 330 8503, Japan
Novartis Investigative Site

Saitama, Saitama, 330-8553, Japan
Novartis Investigative Site

Izumo, Shimane, 693 8501, Japan
Novartis Investigative Site

Hamamatsu, Shizuoka, 431-3192, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 113-8431, Japan
Novartis Investigative Site

Chuo Ku, Tokyo, 104 0045, Japan
Novartis Investigative Site

Edogawa City, Tokyo, 133-0052, Japan
Novartis Investigative Site

Kiyose, Tokyo, 204-8585, Japan
Novartis Investigative Site

Koto Ku, Tokyo, 135 8550, Japan
Novartis Investigative Site

Minato, Tokyo, 108-0073, Japan
Novartis Investigative Site

Minato Ku, Tokyo, 105-8470, Japan
Novartis Investigative Site

Minato-ku, Tokyo, 105-8471, Japan
Novartis Investigative Site

Shibuya City, Tokyo, 150-8935, Japan
Novartis Investigative Site

Shinjuku Ku, Tokyo, 160-0023, Japan
Novartis Investigative Site

Tama, Tokyo, 206-8512, Japan
Novartis Investigative Site

Toyama, Toyama, 930-0194, Japan
Novartis Investigative Site

Higashi Okitama, Yamagata, 9920601, Japan
Novartis Investigative Site

Ube, Yamaguchi, 755-0241, Japan
Novartis Investigative Site

Aomori, 030 8553, Japan
Novartis Investigative Site

Chiba, 261-0001, Japan
Novartis Investigative Site

Hiroshima, 734 8530, Japan
Novartis Investigative Site

Kumamoto, 860-8556, Japan
Novartis Investigative Site

Kumamoto, 861-4193, Japan
Novartis Investigative Site

Osaka, 530 0005, Japan

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER